<unk> , sold under the brand name Revcovi, is a medication for the treatment of the rare disease adenosine deaminase deficiency-SCID in children and adults. It is a recombinant enzyme that is administered weekly by intramuscular injection.<unk>  may interact with PEGylated drugs.<unk> -lvlr was approved by the U.S. Food and Drug Administration (FDA) in 2018. Leadiant Biosciences was awarded a priority review voucher for its development under the pediatric rare diseases program.
Elapegademase
Pegaspargase
Bovhyaluronidase azoximer
Mucrocetin
Apetamin
Angiozyme
Streptokinase
Velmanase alfa